There are more than 65,000 genetic tests available on the market today and new genetic tests are added daily. According to the website GeneTests.org, there are currently more than 650 laboratories manufacturing tests for more than 4,500 disorders. The quick math? There are potentially thousands of different tests for a clinical indication. But how do payers and providers even begin to identify when genetic testing can be useful, let alone which test to use?
Based on the needs of our clients, Hayes has taken the approach of looking at the big picture and asking the most pertinent question, “Does genetic testing have clinical utility?” As genetic testing continues to evolve, new technologies emerge, and encompasses more and more conditions, the overall clinical utility of genetic testing needs to be assessed. Our new tool, the Hayes GTE Indication report, does exactly this—assesses the evidence for the clinical utility of genetic testing for a condition or indication. Using our new product, health plans and health systems may save themselves time and money by answering this question first—before proceeding to the analytical or clinical validity of specific genetic tests.
This report has been strategically designed to accompany the other products in the GTE Program. Once clients have established the clinical utility of genetic testing for an indication via this new report, they will be able to progress through the other resources in the GTE Program to determine the evidence for an individual test and/or how a test stacks up against a competitor. We recently unveiled this innovation to our clients and the response has been overwhelmingly positive with eagerness for more of these new reports.This innovation encompasses that which Hayes strives to do—offer clients relevant, helpful, and unbiased information to support evidence-based decision-making for better patient outcomes. To see what the Hayes GTE Program has to offer, please click here.